MJ UK Mounjaro: The Straightforward Guide to Tirzepatide in Britain

You've searched "MJ UK", here's what that actually means

Plenty of people arrive at this search having heard a friend mention "MJ" or spotted it in a weight-loss group. The abbreviation is informal slang for Mounjaro, Eli Lilly's brand of tirzepatide. The medicine itself is very real and very much available in the UK, but only on prescription, and only after a qualified prescriber has decided it is appropriate for you. No shortcut changes that.

One misconception worth clearing up gently: tirzepatide is not the same as Ozempic or Wegovy. Both of those are semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Mounjaro targets both GIP and GLP-1 receptors at once, which is why the clinical results look meaningfully different from single-pathway options. The distinction matters when you are weighing up which treatment to ask about, our tirzepatide overview goes deeper on the mechanism if you want the full picture.

If you are curious about whether an oral form exists, there is currently no oral version of Mounjaro licensed in the UK. There is, however, a newly approved oral semaglutide tablet (Wegovy in tablet form); our page on oral weight-loss treatments in the UK explains the difference clearly.

What tirzepatide actually does once it is in your system

Each weekly injection activates two receptors involved in appetite regulation and blood-sugar control. The result is a slower rate of gastric emptying (food leaves the stomach more gradually) alongside stronger signals of fullness after eating. Most people find their appetite reduces noticeably, sometimes quite quickly after starting, though the full effect builds over the titration period.

The licensed schedule in the UK begins at 2.5 mg. That starting dose is a settling-in period; the prescriber then increases the dose in steps, typically every four weeks, working up through 5, 7.5, 10 and 12.5 mg toward a maximum of 15 mg. The pace of titration is a clinical decision, not a fixed timetable, your prescriber takes your response and tolerability into account at each stage. For a thorough look at how the clinical trial programme was designed, the Mounjaro trials UK page covers SURMOUNT-1 and the wider evidence base in detail.

The most commonly reported side effects are gastrointestinal: nausea, occasional vomiting, loose stools or constipation, and indigestion. These tend to be most noticeable in the first days after a dose increase and often ease within a week or two as the body adjusts. The Mounjaro information page covers side effects in full, including the signs that warrant prompt medical attention.

Who is likely to meet the eligibility criteria in the UK

The UK licence for Mounjaro as a weight-management medicine covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. BMI thresholds are lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, in line with UK clinical guidance.

A BMI that meets the numbers is the starting point, not the whole picture. A prescriber also considers your medical history, current medicines, and whether any contraindications apply. Pregnancy, breastfeeding, or actively trying to conceive rules out treatment; Mounjaro is not licensed for people under 18. Women taking oral contraceptives should know that the pill's absorption may be affected during the early weeks of Mounjaro treatment and after each dose increase, our dedicated page on Mounjaro and contraception sets out the guidance in plain terms.

NICE recommended tirzepatide for NHS use in December 2024 (TA1026) for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with the NHS rolling out access in phases. Private treatment through a regulated pharmacy follows the licensed criteria directly, without a waiting list, subject to clinical assessment. For a broader sense of what weight-management treatment involves, the weight-loss treatment overview sets out the options.

Getting Mounjaro through a UK pharmacy, what the process looks like

The only lawful route to Mounjaro in the UK is a prescription following a proper clinical assessment. That holds whether you go via your GP, an NHS specialist service, or a regulated online pharmacy. What differs between routes is speed, waiting time, and who bears the cost.

Supply has been constrained at various points since launch. The Mounjaro supply situation in the UK page is kept current with what is known about availability. It is worth reading before you plan your first order, particularly if you are considering a specific dose.

For context on what private treatment typically costs and what a quoted price should include, the how to get Mounjaro page covers pricing transparently, including what legitimate providers include as standard and what the "headline price" sometimes leaves out.

If you have questions about our clinical team or how prescribing decisions are made at nume, our clinical lead's profile is worth a read. When you are ready to find out whether Mounjaro is suitable for you, a free consultation with one of our GPhC-registered prescribers is the natural next step. The NHS's own NICE appraisal of tirzepatide (TA1026) and the NHS tirzepatide medicines page are both worth bookmarking as authoritative, up-to-date references as you do your research.

When you feel ready, start your free consultation and a prescriber will review your details the same day.